Healthcare Industry News: Sanofi-aventis
News Release - April 23, 2007
Prasco Enters into Agreement with sanofi-aventis to Market the Authorized Generic Versions of Ambien(R) (Zolpidem Tartrate) CIVPrasco Expands Authorized Generic Line with Zolpidem Tartrate Tablets 5 mg and 10 mg
CINCINNATI--(HSMN NewsFeed)--Prasco announced today it has signed a distribution and supply agreement with Sanofi-aventis U.S. to launch authorized generic versions of AmbienŽ in the United States. The authorized generic Zolpidem Tartrate will be marketed in 5 mg and 10 mg strengths.
"We are pleased to provide pharmacists and consumers with the authorized generic of Ambien," said Prasco Chief Executive Officer E. Thomas Arington. "As a Prasco authorized generic, Zolpidem Tartrate will provide patients with the same quality and experience as the brand product," stated Arington. "We are especially proud to add Ambien to the growing number of products with Sanofi-aventis, a leader in the pharmaceutical industry."
Prasco intends to begin shipping its Zolpidem Tartrate immediately.
Ambien is indicated for the short-term treatment of insomnia in adults, and had reported sales of $1.7 billion dollars in the last 12 months, with over 18 million prescriptions filled.(1) This agreement is limited to the rights to market the authorized generic of the immediate release formulation of Zolpidem Tartrate. Ambien is a registered trademark of the Sanofi-aventis Group.
Zolpidem Tartrate 5mg and 10 mg tablets are the latest product from Prasco in its rapidly growing authorized generics program. Prasco's mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with an identical brand experience through Prasco authorized generics, which are generic products manufactured by brand companies and marketed as generics under the Prasco private label. The Prasco product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.
The company operates its administrative office and warehouse facilities from Cincinnati, OH including DEA-approved facilities for Schedule II-V controlled drug products.
(1) January 2007 IMS Data
Source: Prasco Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.